Call us on:

Mail us on:
+91 - 44 - 42050273
+91 - 44 - 42050157

Home > Research at ABPL > Our Commitment

Research And Development Activities At Allianz Biosciences Pvt Limited

ABPL is committed to conducting state-of-the-art probiotic research and development in order to be leaders in probiotic research in the area of human and livestock industries such as aquaculture, poultry and dairy.

Rationale of Our Commitment to Provision of High-Level Scientific and Clinical Data

As the market for probiotic-containing products has grown rapidly, the WHO and FAO met in 2001 to provide guidelines for standardisation of probiotics. In summary, they stated that probiotic microbes should be capable of surviving passage through the digestive tract and have the capability to proliferate, meaning they must:

  • be resistant to gastric juices (acid and bile)
  • grow in the presence of bile as in the gut
  • be able to colonise the human intestinal tract

More importantly, the organisms should be identified by strain using molecular tools.

In order to be termed a "probiotic", the WHO/FAO also decreed that the probiotic microbe must be able to confer defined health benefits based on clinical data on the specific strain. WHO pointed out that not all probiotics are capable of meeting the criteria - therefore it is essential to define the specific strain used in trials.

Probiotic criteria

In general, it is agreed that the selection criteria for a lactic acid bacterium to be cited as a 'probiotic' should be : 

  • non-pathogenic; 
  • withstand incorporation into a delivery vehicle at high cell counts, and 
  • remain viable throughout the shelf-life of the product;
  • withstand transit through the gastrointestinal tract, that is, show acid and bile tolerance; 
  • be able to adhere to cells of the intestinal epithelium and/or colonize the lumen of the tract;
  • show antagonistic activity towards enteric pathogens and/or 
  • provide demonstrated health benefits.